DexCom faces challenges in the diabetes market, resulting in a drop in stock valuation. Despite this, the company is poised for success moving forward. With its continuous glucose monitoring systems, DexCom helps diabetes patients make better health decisions, leading to improved outcomes. The company has a large global opportunity and aims to capitalize on it.

While DexCom experienced a decline in financial results due to unexpected rebates in the U.S., the company remains focused on the CGM market. With an increasing installed base and expanding addressable market, DexCom is set to grow revenue and earnings. The stock’s forward P/E ratio is high but historically still delivers market-beating returns.

DexCom’s main competitor, Abbott Laboratories, poses a challenge, but there is room for both companies to succeed in the CGM market. DexCom benefits from a network effect, making its ecosystem attractive to developers and patients. The company’s focus on technology compatibility and user appeal positions it as a leader in CGM for years to come, potentially rebounding from last year’s performance.

The Motley Fool’s expert analysts suggest DexCom could be a top investment. With a history of high returns, DexCom’s potential for growth in the next five to 10 years is promising. By leveraging its technology and market position, DexCom aims to deliver superior returns and maintain its leadership in the CGM market.

Read more at Yahoo Finance: Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years